BACKGROUND: Patients with early-onset colorectal cancer (CRC) or those with multiple tumours associated with hereditary non-polyposis colorectal cancer (HNPCC) raise suspicion of the presence of germline DNA mismatch repair (MMR) gene mutations. AIM: To analyse the value of family history, microsatellite instability (MSI) analysis and MMR protein staining in the tumour to predict the presence of an MMR gene mutation in such patients. METHODS: In 281 patients diagnosed with CRC before the age of 50 years or with CRC and at least one additional HNPCC-associated cancer, germline mutation analysis in MLH1, MSH2 and MSH6 was carried out with denaturing gradient gel electrophoresis and multiplex ligation-dependent probe amplification. MSI analysis with five consensus markers and MMR protein staining for MLH1, MSH2 and MSH6 were carried out in the tumours. RESULTS: 25 pathogenic mutations (8 in MLH1, 9 in MSH2 and 8 in MSH6) were found. MSI analysis missed three and immunohistochemistry (IHC) missed two mutation carriers. Sensitivities of family history, MSI analysis and IHC for the presence of a mutation were 76%, 82% and 88%, specificities were 64%, 70% and 84%, and positive predictive values were 19%, 23% and 38%, respectively. Multivariate analysis showed the highest odds ratio for IHC (38.3, 95% confidence interval 9.0 to 184). Prevalence of pathogenic germline MMR gene mutations in patients with CRC before the age of 50 years was 6% and in those with > or =2 HNPCC-associated tumours was 22%. In the second group, no mutation carriers were found among the 29 patients who were diagnosed with their first tumour after the age of 60 years. CONCLUSION: Family history, MSI analysis and IHC are indicative parameters to select patients with CRC for MMR gene mutation analysis. The data show that IHC is the best single selection criterion.
BACKGROUND:Patients with early-onset colorectal cancer (CRC) or those with multiple tumours associated with hereditary non-polyposis colorectal cancer (HNPCC) raise suspicion of the presence of germline DNA mismatch repair (MMR) gene mutations. AIM: To analyse the value of family history, microsatellite instability (MSI) analysis and MMR protein staining in the tumour to predict the presence of an MMR gene mutation in such patients. METHODS: In 281 patients diagnosed with CRC before the age of 50 years or with CRC and at least one additional HNPCC-associated cancer, germline mutation analysis in MLH1, MSH2 and MSH6 was carried out with denaturing gradient gel electrophoresis and multiplex ligation-dependent probe amplification. MSI analysis with five consensus markers and MMR protein staining for MLH1, MSH2 and MSH6 were carried out in the tumours. RESULTS: 25 pathogenic mutations (8 in MLH1, 9 in MSH2 and 8 in MSH6) were found. MSI analysis missed three and immunohistochemistry (IHC) missed two mutation carriers. Sensitivities of family history, MSI analysis and IHC for the presence of a mutation were 76%, 82% and 88%, specificities were 64%, 70% and 84%, and positive predictive values were 19%, 23% and 38%, respectively. Multivariate analysis showed the highest odds ratio for IHC (38.3, 95% confidence interval 9.0 to 184). Prevalence of pathogenic germline MMR gene mutations in patients with CRC before the age of 50 years was 6% and in those with > or =2 HNPCC-associated tumours was 22%. In the second group, no mutation carriers were found among the 29 patients who were diagnosed with their first tumour after the age of 60 years. CONCLUSION: Family history, MSI analysis and IHC are indicative parameters to select patients with CRC for MMR gene mutation analysis. The data show that IHC is the best single selection criterion.
Authors: M A Rodriguez-Bigas; C R Boland; S R Hamilton; D E Henson; J R Jass; P M Khan; H Lynch; M Perucho; T Smyrk; L Sobin; S Srivastava Journal: J Natl Cancer Inst Date: 1997-12-03 Impact factor: 13.506
Authors: Annemarie H van der Hout; Ans M W van den Ouweland; Rob B van der Luijt; Hans J P Gille; Daniëlle Bodmer; Hennie Brüggenwirth; Inge M Mulder; Pieter van der Vlies; Peter Elfferich; Maarten T Huisman; Annelies M ten Berge; Joan Kromosoeto; Rumo P M Jansen; Patrick H A van Zon; Thyrsa Vriesman; Neeltje Arts; Majella Boutmy-de Lange; Jan C Oosterwijk; Hanne Meijers-Heijboer; Margreet G E M Ausems; Nicoline Hoogerbrugge; Senno Verhoef; Dicky J J Halley; Yvonne J Vos; Frans Hogervorst; Marjolijn Ligtenberg; Robert M W Hofstra Journal: Hum Mutat Date: 2006-07 Impact factor: 4.878
Authors: Hidewaki Nakagawa; Janet C Lockman; Wendy L Frankel; Heather Hampel; Kelle Steenblock; Lawrence J Burgart; Stephen N Thibodeau; Albert de la Chapelle Journal: Cancer Res Date: 2004-07-15 Impact factor: 12.701
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Andrea E de Jong; Marjo van Puijenbroek; Yvonne Hendriks; Carli Tops; Juul Wijnen; Margreet G E M Ausems; Hanne Meijers-Heijboer; Anja Wagner; Theo A M van Os; Annette H J T Bröcker-Vriends; Hans F A Vasen; Hans Morreau Journal: Clin Cancer Res Date: 2004-02-01 Impact factor: 12.531
Authors: Samar Hassen; Bruce M Boman; Nawab Ali; Marcie Parker; Chandra Somerman; Zohra J Ali-Khan Catts; Akhtar A Ali; Jeremy Z Fields Journal: J Exp Clin Cancer Res Date: 2011-10-21
Authors: Jose Perea; Edurne Alvaro; Yolanda Rodríguez; Cristina Gravalos; Eva Sánchez-Tomé; Barbara Rivera; Francisco Colina; Pablo Carbonell; Rogelio González-Sarmiento; Manuel Hidalgo; Miguel Urioste Journal: World J Gastroenterol Date: 2010-08-07 Impact factor: 5.742
Authors: Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst Journal: Hum Mutat Date: 2008-11 Impact factor: 4.878
Authors: L I Overbeek; R P Hermens; J H van Krieken; E M Adang; M Casparie; F M Nagengast; M J Ligtenberg; N Hoogerbrugge Journal: Virchows Arch Date: 2010-04-09 Impact factor: 4.064
Authors: Marievelisse Soto-Salgado; Erick Suárez; William Calo; Marcia Cruz-Correa; Nayda R Figueroa-Vallés; Ana P Ortiz Journal: Cancer Date: 2009-07-01 Impact factor: 6.860
Authors: A P Knopperts; M Nielsen; R C Niessen; C M J Tops; B Jorritsma; J Varkevisser; J Wijnen; C L E Siezen; R C Heine-Bröring; H J van Kranen; Y J Vos; H Westers; E Kampman; R H Sijmons; F J Hes Journal: Fam Cancer Date: 2013-03 Impact factor: 2.375
Authors: Rein P Stulp; Johanna C Herkert; Arend Karrenbeld; Bart Mol; Yvonne J Vos; Rolf H Sijmons Journal: Hered Cancer Clin Pract Date: 2008-02-15 Impact factor: 2.857